Arturo Ottavio Rinaldi

Arturo Ottavio Rinaldi

Auto-generated profile, based on publicly available information

Arturo Ottavio Rinaldi

Swiss Institute of Allergy and Asthma Research (SIAF) University of Zürich Davos Switzerland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MAMubeccel Akdis
Mubeccel Akdis
AAAlar Aab
Alar Aab
CACan Altunbulakli
Can Altunbulakli
KAKursat Azkur
Kursat Azkur
RCRita A. Costa
Rita A. Costa
CACezmi A. Akdis
Cezmi A. Akdis

6 December 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
URUrszula Radzikowska
Urszula Radzikowska
ARArturo O. Rinaldi
Arturo O. Rinaldi
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
DKDilara Karaguzel
Dilara Karaguzel
Marzena WojcikMarzena Wojcik
Marzena Wojcik
MSMilena Sokolowska
Milena Sokolowska
Diet-derived fatty acids (FAs) are essential sources of energy and fundamental structural components of cells. They also play important roles in the modulation of immune responses in health and disease. Saturated and unsaturated FAs influence the effector and regulatory functions of innate and adaptive immune cells by changing membrane composition and fluidity and by acting through specific receptors. Impaired balance of saturated/unsaturated FAs, as well as n-6/n-3 polyunsaturated FAs has significant consequences on immune system homeostasis, contributing to the development of many allergic, autoimmune, and metabolic diseases. In this paper, we discuss up-to-date knowledge and the clinical relevance of the influence of dietary FAs on the biology, homeostasis, and functions of epithelial cells, macrophages, dendritic cells, neutrophils, innate lymphoid cells, T cells and B cells. Additionally, we review the effects of dietary FAs on the pathogenesis of many diseases, including asthma, allergic rhinitis, food allergy, atopic dermatitis, rheumatoid arthritis, multiple sclerosis as well as type 1 and 2 diabetes.

14 September 2021 in Allergy
Verified
Journal Article
Open access
PDF file
IOIsmail Ogulur
Ismail Ogulur
YPYagiz Pat
Yagiz Pat
OAOzge Ardicli
Ozge Ardicli
EBElena Barletta
Elena Barletta
LCLacin Cevhertas
Lacin Cevhertas
CACezmi A. Akdis
Cezmi A. Akdis
During the past years, there has been a global outbreak of allergic diseases, presenting a considerable medical and socioeconomical burden. A large fraction of allergic diseases is characterized by a type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, eosinophils, mast cells, and M2 macrophages. Biomarkers are valuable parameters for precision medicine as they provide information on the disease endotypes, clusters, precision diagnoses, identification of therapeutic targets, and monitoring of treatment efficacies. The availability of powerful omics technologies, together with integrated data analysis and network‐based approaches can help the identification of clinically useful biomarkers. These biomarkers need to be accurately quantified using robust and reproducible methods, such as reliable and point‐of‐care systems. Ideally, samples should be collected using quick, cost‐efficient and noninvasive methods. In recent years, a plethora of research has been directed toward finding novel biomarkers of allergic diseases. Promising biomarkers of type 2 allergic diseases include sputum eosinophils, serum periostin and exhaled nitric oxide. Several other biomarkers, such as pro‐inflammatory mediators, miRNAs, eicosanoid molecules, epithelial barrier integrity, and microbiota changes are useful for diagnosis and monitoring of allergic diseases and can be quantified in serum, body fluids and exhaled air. Herein, we review recent studies on biomarkers for the diagnosis and treatment of asthma, chronic urticaria, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, food allergies, anaphylaxis, drug hypersensitivity and allergen immunotherapy. In addition, we discuss COVID‐19 and allergic diseases within the perspective of biomarkers and recommendations on the management of allergic and asthmatic patients during the COVID‐19 pandemic.

30 September 2020 in Allergy
Verified
Journal Article
Open access
PDF file
LCLacin Cevhertas
Lacin Cevhertas
IOIsmail Ogulur
Ismail Ogulur
DMDebbie J. Maurer
Debbie J. Maurer
DBDaniel Burla
Daniel Burla
MDMei Ding
Mei Ding
CACezmi A. Akdis
Cezmi A. Akdis
In this review, we discuss recent publications on asthma and review the studies that have reported on the different aspects of the prevalence, risk factors and prevention, mechanisms, diagnosis, and treatment of asthma. Many risk and protective factors and molecular mechanisms are involved in the development of asthma. Emerging concepts and challenges in implementing the exposome paradigm and its application in allergic diseases and asthma are reviewed, including genetic and epigenetic factors, microbial dysbiosis, and environmental exposure, particularly to indoor and outdoor substances. The most relevant experimental studies further advancing the understanding of molecular and immune mechanisms with potential new targets for the development of therapeutics are discussed. A reliable diagnosis of asthma, disease endotyping, and monitoring its severity are of great importance in the management of asthma. Correct evaluation and management of asthma comorbidity/multimorbidity, including interaction with asthma phenotypes and its value for the precision medicine approach and validation of predictive biomarkers, are further detailed. Novel approaches and strategies in asthma treatment linked to mechanisms and endotypes of asthma, particularly biologicals, are critically appraised. Finally, due to the recent pandemics and its impact on patient management, we discuss the challenges, relationships, and molecular mechanisms between asthma, allergies, SARS‐CoV‐2, and COVID‐19.

1 June 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
HMHideaki Morita
Hideaki Morita
TKTerufumi Kubo
Terufumi Kubo
BRBeate Rückert
Beate Rückert
ARAvinash Ravindran
Avinash Ravindran
MSMichael B. Soyka
Michael B. Soyka
CACezmi A. Akdis
Cezmi A. Akdis

27 December 2018 in Allergy
Verified
Journal Article
Closed access
PDF file
WBWeronika Barcik
Weronika Barcik
Benoit PuginBenoit Pugin
Benoit Pugin
MBMarina Sabaté Brescó
Marina Sabaté Brescó
PWPatrick Westermann
Patrick Westermann
ARArturo Rinaldi
Arturo Rinaldi
LOLiam O’Mahony
Liam O’Mahony